William Blair Has Pessimistic Outlook of PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) - Analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of PROCEPT BioRobotics in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of ($0.48) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics' Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.94) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%.

Several other research firms have also recently issued reports on PRCT. Jefferies Financial Group initiated coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They issued a "hold" rating and a $95.00 price objective on the stock. Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Truist Financial reaffirmed a "buy" rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics has an average rating of "Moderate Buy" and a consensus target price of $94.29.

Remove Ads

PROCEPT BioRobotics Stock Up 7.2 %

Shares of NASDAQ PRCT traded up $4.38 during midday trading on Friday, hitting $64.98. The stock had a trading volume of 1,873,684 shares, compared to its average volume of 953,062. The business's 50 day moving average is $74.19 and its 200-day moving average is $80.04. PROCEPT BioRobotics has a 52 week low of $45.56 and a 52 week high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.39 billion, a P/E ratio of -33.32 and a beta of 1.03.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 28,092 shares of the company's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now owns 52,472 shares in the company, valued at $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of the firm's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the transaction, the chief executive officer now directly owns 152,762 shares in the company, valued at $14,851,521.64. This trade represents a 14.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.40% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Creative Planning raised its holdings in PROCEPT BioRobotics by 88.9% during the third quarter. Creative Planning now owns 9,948 shares of the company's stock valued at $797,000 after acquiring an additional 4,681 shares during the period. International Assets Investment Management LLC grew its position in shares of PROCEPT BioRobotics by 12,919.5% during the third quarter. International Assets Investment Management LLC now owns 52,078 shares of the company's stock worth $4,172,000 after purchasing an additional 51,678 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in PROCEPT BioRobotics by 178.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock valued at $89,000 after purchasing an additional 713 shares during the period. Oak Ridge Investments LLC purchased a new position in PROCEPT BioRobotics in the 3rd quarter worth approximately $1,942,000. Finally, Americana Partners LLC purchased a new position in PROCEPT BioRobotics in the 3rd quarter worth approximately $1,494,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).